Pixantrone: a new agent for relapsed aggressive lymphomas

Affiliations

Comment

Fernando Cabanillas. Lancet Oncol. 2012 Jul.

. 2012 Jul;13(7):654-6.

doi: 10.1016/S1470-2045(12)70232-2. Epub 2012 May 30.

¹ Auxilio Centro de Cáncer, Hospital Auxilio Mutuo, San Juan, PR 00918, Puerto Rico. fcabanil@mdanderson.org

No abstract available

Comment on

Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.
Pettengell R, Coiffier B, Narayanan G, de Mendoza FH, Digumarti R, Gomez H, Zinzani PL, Schiller G, Rizzieri D, Boland G, Cernohous P, Wang L, Kuepfer C, Gorbatchevsky I, Singer JW. Pettengell R, et al. Lancet Oncol. 2012 Jul;13(7):696-706. doi: 10.1016/S1470-2045(12)70212-7. Epub 2012 May 30. Lancet Oncol. 2012. PMID: 22652183 Clinical Trial.